Dominic Surry, Associate Director of In Vitro Screening & Profiling at AstraZeneca, joins Helen Winsor from Pharma IQ, to discuss clinically relevant drug transporters. He explains the importance of exploring and understanding the forthcoming FDA/EMA regulations in order to develop transporter assays and identify transporter substrates, establish IVIVC and evaluate the clinical relevance. During the interview, he predicts which families of transporters will be the most important for drug development; he discusses the critical success factors and common hurdles in studying transporter interactions in the clinical setting; and talks about the importance of pre-clinical transporter data in clinical assessment. Surry also discusses the consequences of not having thorough transporter studies for drug applications, patients and prescribers; and pinpoints where he commonly sees gaps in clinical methodologies for assessing transporter based DDIs – and strategic approaches to bridging these.

[inlinead]